Compare LFVN & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFVN | SCLX |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.9M | 52.9M |
| IPO Year | 1996 | N/A |
| Metric | LFVN | SCLX |
|---|---|---|
| Price | $4.40 | $6.33 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 97.6K | 30.7K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.19% | N/A |
| EPS Growth | ★ 226.09 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $203,204,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $749.70 |
| P/E Ratio | $22.63 | ★ N/A |
| Revenue Growth | ★ 1.86 | N/A |
| 52 Week Low | $3.90 | $0.18 |
| 52 Week High | $16.14 | $34.27 |
| Indicator | LFVN | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 38.05 | 30.18 |
| Support Level | $4.32 | $4.56 |
| Resistance Level | $5.37 | $7.50 |
| Average True Range (ATR) | 0.29 | 0.62 |
| MACD | -0.04 | -0.13 |
| Stochastic Oscillator | 23.70 | 3.50 |
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.